• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对《氟维司群在激素受体阳性晚期乳腺癌绝经后患者中的疗效和安全性:系统文献综述与荟萃分析》的更正

Correction to: Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.

作者信息

Wang Jiayu, Xu Binghe, Wang Wenna, Zhai Xiaoyu, Chen Xuelian

机构信息

Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, #17 Panjiayuan Nanli, Beijing, China.

出版信息

Breast Cancer Res Treat. 2019 Jan;173(2):487. doi: 10.1007/s10549-018-5047-9.

DOI:10.1007/s10549-018-5047-9
PMID:30470975
Abstract

In the original publication of the article, the authors' affiliation was published incorrectly. The corrected affiliation is given in this correction. The author also found few corrections in the article which are given below.

摘要

在该文章的原始发表中,作者的单位信息发布有误。本勘误给出了更正后的单位信息。作者还发现文章中有一些勘误,如下所示。

相似文献

1
Correction to: Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.对《氟维司群在激素受体阳性晚期乳腺癌绝经后患者中的疗效和安全性:系统文献综述与荟萃分析》的更正
Breast Cancer Res Treat. 2019 Jan;173(2):487. doi: 10.1007/s10549-018-5047-9.
2
Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.氟维司群治疗激素受体阳性晚期乳腺癌绝经后患者的疗效和安全性:系统文献回顾和荟萃分析。
Breast Cancer Res Treat. 2018 Oct;171(3):535-544. doi: 10.1007/s10549-018-4867-y. Epub 2018 Jul 4.
3
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.在绝经后激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌患者中,比较布帕利西布联合氟维司群与安慰剂联合氟维司群的疗效(BELLE-2):一项随机、双盲、安慰剂对照的3期试验。
Lancet Oncol. 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30.
4
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.氟维司群:用于抗雌激素治疗后疾病进展的绝经后激素受体阳性转移性乳腺癌女性患者的应用综述
Drugs. 2004;64(6):633-48. doi: 10.2165/00003495-200464060-00009.
5
Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.关于氟维司群(一种用于晚期乳腺癌的独特抗雌激素治疗药物)的疗效和安全性的新数据。
Expert Opin Drug Saf. 2011 Sep;10(5):819-26. doi: 10.1517/14740338.2011.595560. Epub 2011 Jun 24.
6
Correction to: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.对《绝经后雌激素受体阳性乳腺癌患者睾酮和肥胖症预后价值的观察性研究》的更正
BMC Cancer. 2018 Sep 10;18(1):876. doi: 10.1186/s12885-018-4799-2.
7
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.氟维司群 500 mg 对比阿那曲唑 1 mg 治疗激素受体阳性晚期乳腺癌(FALCON):一项国际、随机、双盲、III 期临床试验。
Lancet. 2016 Dec 17;388(10063):2997-3005. doi: 10.1016/S0140-6736(16)32389-3. Epub 2016 Nov 29.
8
Correction to: Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin.对《金诺芬三种拟卤化物衍生物的结构与溶液化学、抗增殖作用及血清白蛋白结合》的修正
Biometals. 2019 Dec;32(6):949. doi: 10.1007/s10534-019-00227-y.
9
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.网络荟萃分析:比较500毫克氟维司群与其他疗法治疗先前内分泌治疗失败后的绝经后、雌激素受体阳性晚期乳腺癌的总生存期
Clin Breast Cancer. 2016 Jun;16(3):188-95. doi: 10.1016/j.clbc.2016.02.007. Epub 2016 Feb 11.
10
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.氟维司群在绝经后转移性乳腺癌患者治疗中的作用。
Expert Rev Clin Pharmacol. 2016 Sep;9(9):1153-61. doi: 10.1080/17512433.2016.1215243. Epub 2016 Aug 12.